Eli Lilly And Company

This study looks at the long-term safety of an experimental drug called LY4256984 for people with amyotrophic lateral sclerosis (ALS). It is an extension of an earlier study and will follow 32 participants for about 96 weeks. The main goal is to track any serious side effects rel…

This study tests a once-daily pill called orforglipron in adults with type 2 diabetes who plan to fast during Ramadan. The goal is to see if the drug helps control blood sugar and weight without causing harm. About 130 participants will take the pill for up to 48 weeks, with clin…

This early-stage study tests a new drug called LY4152199 in adults with B-cell cancers (like certain lymphomas) that have come back or not responded to prior treatments. The drug is designed to help the body's immune cells attack cancer cells. The main goals are to find the safes…

This study tests whether donanemab can slow down memory and thinking problems in people with early cognitive decline who also have signs of Lewy body dementia and Alzheimer's-related brain changes. About 350 participants will receive either the drug or a placebo for 1.5 years. Th…

This study tests a new drug, imlunestrant, in 600 premenopausal women with estrogen receptor-positive, HER2-negative breast cancer. It compares how the drug affects tumor cells and ovaries versus tamoxifen, with or without ovarian suppression. The goal is to find a better treatme…

This study looks at whether people with Alzheimer's who have already taken donanemab benefit from getting it once a year. About 550 participants will be followed for up to 2.5 years to see if their thinking and memory stay stable. The goal is to find a convenient way to manage th…

This study tests whether two experimental drugs, macupatide and eloralintide, can help adults with obesity or overweight lose weight safely. About 400 participants will receive the drugs alone, together, or a placebo for around 64 weeks. The main goal is to see how much body weig…

This study tests a drug called lepodisiran in 252 adults with high levels of Lp(a), a protein linked to heart disease. Participants must have heart disease or be at risk for a first heart event. The drug is given as an injection and compared to a placebo to see if it reduces plaq…

This study tests a new, non-invasive eye scan that uses artificial intelligence to look for changes linked to Alzheimer's disease. Researchers will compare the scan results with blood tests in 200 UAE adults who have mild memory problems. The goal is to see if this quick, painles…

This study tests whether the drug donanemab can delay memory and thinking problems in Chinese adults who are at risk for Alzheimer's disease. About 140 participants with normal thinking skills but signs of brain changes will receive either donanemab or a placebo through an IV eve…

This study tests a new medicine called LY4065967 for people with long-term low back pain. About 150 adults will receive either the drug or a placebo to see if it safely reduces pain and improves sleep. The goal is to find better treatment options for chronic pain.

This early-phase study tests a single dose of LY3971297 in 90 adults with heart failure to see if it is safe and what side effects occur. Participants will have one 4-day hospital stay and five outpatient visits over about two months. The goal is to gather safety information, not…

This study tests a new medicine (LY4065967) to see if it safely reduces knee pain from osteoarthritis. About 150 adults with long-term knee pain will receive either the drug or a placebo. The goal is to measure pain relief and improvement in daily function over time.

This study checks the long-term safety of experimental treatments for amyotrophic lateral sclerosis (ALS). It enrolls 32 people who finished an earlier ALS drug study and will follow them for at least 96 weeks. The main goal is to see how many participants can be assigned to each…

This study tests 3 different forms (a tablet and 2 types of capsule) of the experimental drug LY4065967 in 36 healthy adults. The goal is to measure how much and how quickly each form gets into the bloodstream, and to check for side effects. Participants will stay in a research u…

This study looks at how the antifungal drug itraconazole changes the way the body processes a new drug called LY4395089. Fourteen healthy adults will stay at a research unit for 15 days and give blood samples to measure drug levels. The goal is to understand drug interactions, no…

This study looks at whether a simple, wearable sleep monitor can give the same results as a full lab sleep test in people with early or no Alzheimer's symptoms. About 35 participants will wear both devices at the same time in a lab and then use the wearable at home. The goal is t…

This early-stage study looks at how the body absorbs eltrekibart when given as a shot under the skin. It involves 60 healthy adults who will receive a single dose. The goal is to compare two different versions of the drug and check for safety. The study lasts about 17 weeks.

This early-stage study tests a new drug, LY3439539, in 30 people with mild-to-moderate Alzheimer's. The main goal is to see how the drug changes certain proteins in the spinal fluid that are linked to Alzheimer's. Participants will have monthly visits over about 9 months. This st…

This early-stage study tests a new drug called LY4302814 in 150 healthy adults to see if it is safe and how the body handles it. Participants will have blood tests and stay overnight at a clinic for up to 9 days. The study lasts about 6 months and does not aim to treat any diseas…

This study looks at how much of the drug mirikizumab gets into breast milk. It involves 14 breastfeeding women who already take mirikizumab for inflammatory bowel disease. Researchers will collect milk samples to measure drug levels and check infant safety. The goal is to provide…